article thumbnail

MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment

Digital Health Global

The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process. “ Our mutual dedication to building new approaches to pharmaceutical drug development and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably.

article thumbnail

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

Digital Health Global

With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Debiopharm Innovation Fund Launches New Seed Funding Activity to Accelerate Digital Transformation of Cancer Care and Pharma R&D

Digital Health Global

Investments will focus on the next generation of pharma R&D to accelerate drug development, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.

article thumbnail

Patients and Industry: Starting Our New Life Together in 2023

Society for Participatory Medicine

The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. You may now kiss the cancer survivor. Global regulatory bodies took note, as similar direction was put forth by the EMA under the ICH.

BioTech 144
article thumbnail

Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M

Lloyd Price

billion valuation in the last fundraising in early 2017, according to Lagniappe. and pharmaceutical entrepreneur Robert Duggan. But key facets of its business didn’t develop as planned, say people familiar with the company. That marks an 80% decline from the estimated $1.6 DNA-sequencing company Illumina Inc.,

article thumbnail

Asaya and medical cannabis care in the era of personalised medicine

Lloyd Price

Desperate for medical insights without delay, researchers, pharmaceutical companies and government agencies turned to health information captured through real-world data sources. A new medication is introduced to the market via legislation rather than through formal drug development practices (3); 3. 6 May 2017.

article thumbnail

Digital Therapeutics: the keys to succeed!

Digital Health Today

They have the potential to become a game changer in healthcare for patients, healthcare professionals, pharmaceuticals and insurance companies. The Digital Therapeutics Alliance developed a definition to differentiate DTx solutions from health and wellness apps. When working with pharmaceuticals, stick to pharma deal structure.